Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Strong-Buy” by StockNews.com

Collegium Pharmaceutical is a biopharmaceutical company that specializes in developing and commercializing branded prescription drugs for pain management and other central nervous system disorders. The company's flagship product is Xyrem (sodium oxybate), which is used to treat narcolepsy, a sleep disorder characterized by excessive daytime sleepiness.

On August 19, 2021, StockNews.com upgraded its recommendation on Collegium Pharmaceutical from "Hold" to "Strong-Buy," citing the company's strong financial performance and growth prospects. The upgrade was based on several factors, including the company's growing revenue and profitability, as well as its expanding product portfolio and increasing market share in the pain management and central nervous system disorder markets.

According to the report, Collegium Pharmaceutical's revenue for the second quarter of 2021 was $37.4 million, representing a 65% increase from the same period last year. The company's net income for the same period was $18.9 million, up from a loss of $1.4 million in the second quarter of 2020.

In addition to Xyrem, Collegium Pharmaceutical has several other products in development, including Nuvasive (sodium oxybate oral solution) for the treatment of excessive daytime sleepiness associated with narcolepsy, and Cogentin (procyclidine hydrochloride) for the treatment of Parkinson's disease-related psychosis. The company also has a pipeline of potential new products in various stages of development.

Overall, StockNews.com believes that Collegium Pharmaceutical is well-positioned to continue its growth and success due to its strong financial performance, expanding product portfolio, and increasing market share.